Iterion Therapeutics confirms safety of tegavivint following completion of enrollment in phase 1/2a expansion study.
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings.
Iterion Therapeutics Initiates Enrollment of Phase 2a Dose Expansion Study of Tegavivnt in Patients with Desmoid Tumors.
Iterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase 1 clinical study of Tegavivint, its lead therapeutic candidate, in patients with desmoid tumors that are unresectable and symptomatic or progressive.
